Key Points Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about effectiveness. 10 stocks we like better than Grail › Multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) stock surged 55% through Friday morning after the Food and Drug Administration (FDA) voted favorably on its Galleri MCED test. The vote opens the pathway for the FDA to grant premarket approval to Galleri and, in turn, for increased adoption by medical bodies and insurers.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.